| 1 | Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. 2021;11: doi: 10.1038/s41598-021-82068-9 |
| 2 | Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. 2021;13:2139 doi: 10.3390/cancers13092139 |
| 3 | Design, Synthesis, Molecular Docking, and Biological Studies of New Heterocyclic
Compounds Derived from β-Diketones as Novel EGFR and Pim-1 Inhibitors
Endowed with Antitumor Activity. 2022;22:2558 doi: 10.2174/1871520622666220112104320 |
| 4 | A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. 2020;255:117866 doi: 10.1016/j.lfs.2020.117866 |
| 5 | Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells. 2023;79:129066 doi: 10.1016/j.bmcl.2022.129066 |
| 6 | PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. 2020;5: doi: 10.1038/s41392-020-0109-y |
Journal of Cancer Metastasis and Treatment
